Abstract
MiR-202, part of the let-7 family, plays a role in cell division and tumor development, especially in breast cancer (BC) among females. We have conducted a detailed review on new biomarkers to enhance BC screening and enable early diagnosis, particularly in younger women. Early detection and monitoring drug responses are crucial for optimal BC therapy, prompting the need for new biomarkers in diagnosis and prognosis. This review discusses recent findings on microRNAs in detecting, analyzing, and treating breast cancer (miRNA-BC). Although breast cancer patients often start treatment with radiotherapy, its effectiveness may decline with radiation resistance. This review study compares docetaxel-resistant breast cancer (DRBC) and docetaxel-sensitive cell lines, exploring the role of non-coding RNAs, especially circular RNAs (circRNAs), in DRBC development and identifying predictive biomarkers for taxane-containing therapies. MicroRNA sequencing and bioinformatics predict differences in microRNA expression, genes, and pathways between breast cancer cell types. Current evidence suggests that miR-202 dysregulation is linked to signaling pathways, influencing its anti- or pro-tumorigenic effects, showcasing its potential as a diagnostic biomarker.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
